UK Offers 14-Day Approvals For Lowest-Risk Phase III/IV Trials

 
• By Vibha Sharma

The Medicines and Healthcare products Regulatory Agency says it is in “everyone’s best interest” if clinical trial sponsors seeking UK approval for low-risk Phase III and IV studies make use of its new notification scheme that will cut the 30-day statutory evaluation timeline by more than half.

Close-up at medium level of Risk assessment matrix table paper document. Industrial and business planning object. Selective focus at the medium text.
UK Is Taking A Risk-Proportionate Approach To Processing Initial Clinical Trial Applications • Source: Shutterstock

More from United Kingdom

More from Europe